机构:[1]School of Medicine, Nankai University, Tianjin,[2]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University,四川大学华西医院[3]Department of Immunology, School of Basic Medicine, Peking Union Medical College, Beijing, People’s Republic of China[4]Immunology Research Center, National Health Research Institutes, Miaoli, Taiwan[5]Department of Cell and Molecular Biology, Scripps Research Institute, La Jolla, California
National Key Scientific
Research Projects (2013CB967200), the National Natural Science Foundation
of China Overseas Cooperation Fund (31428013), the National Natural
Science Foundation of China General Project (81272316 and 81273331),
and the Program of International S&T Cooperation (2012DFA10650).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类|2 区医学
小类|2 区免疫学2 区传染病学2 区微生物学
最新[2023]版:
大类|2 区医学
小类|2 区免疫学2 区传染病学2 区微生物学
第一作者:
第一作者机构:[1]School of Medicine, Nankai University, Tianjin,[2]Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University,
通讯作者:
通讯机构:[1]School of Medicine, Nankai University, Tianjin,[*1]School of Medicine, Nankai University, Tianjin 300071, PR China
推荐引用方式(GB/T 7714):
Chang Antao,Chen Yanan,Shen Wenzhi,et al.Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway.[J].The Journal of infectious diseases.2015,212(9):1509-20.doi:10.1093/infdis/jiv221.
APA:
Chang Antao,Chen Yanan,Shen Wenzhi,Gao Ruifang,Zhou Wei...&Xiang Rong.(2015).Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway..The Journal of infectious diseases,212,(9)
MLA:
Chang Antao,et al."Ifit1 Protects Against Lipopolysaccharide and D-galactosamine-Induced Fatal Hepatitis by Inhibiting Activation of the JNK Pathway.".The Journal of infectious diseases 212..9(2015):1509-20